{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:26:00Z","timestamp":1792218360163,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.soncn.2024.151583","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:56:48Z","timestamp":1707458208000},"page":"151583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Influences Shaping Clinicians\u2019 Monoclonal Antibody and Immune Checkpoint Inhibitor Preparation and Administration Management Practices: A Systematic Review"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1787-4855","authenticated-orcid":false,"given":"Angela","family":"Ballard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Ogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.soncn.2024.151583_bib0001","first-page":"20","article-title":"Combination immunotherapy: the next frontier for oncology nursing care","volume":"35","author":"Chris","year":"2020","journal-title":"ONS Voice"},{"issue":"1","key":"10.1016\/j.soncn.2024.151583_bib0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1078155217743095","article-title":"Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies","volume":"25","author":"Bauters","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 6a","key":"10.1016\/j.soncn.2024.151583_bib0003","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.12968\/bjon.2015.24.Sup16a.S3","article-title":"A cautious approach to handling MABs is recommended","volume":"24","author":"Meade","year":"2015","journal-title":"Br J Nurs (Mark Allen Publishing)"},{"key":"10.1016\/j.soncn.2024.151583_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2017.10.002","article-title":"Innovative therapy, monoclonal antibodies and beyond","volume":"38","author":"Di Nicola","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"issue":"Suppl 3","key":"10.1016\/j.soncn.2024.151583_bib0005","first-page":"S1","article-title":"ISOPP standards for the safe handling of cytotoxics","volume":"28","author":"O'Conner","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.soncn.2024.151583_bib0006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab: the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.soncn.2024.151583_bib0007","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CMAR.S120589","article-title":"Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape","volume":"9","author":"Subramanian","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.soncn.2024.151583_bib0008","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/btpr.2066","article-title":"Biosimilars advancements: moving on to the future","volume":"31","author":"Tsuruta","year":"2015","journal-title":"Biotechnol Progress"},{"issue":"2","key":"10.1016\/j.soncn.2024.151583_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/17.CJON.S2.13-21","article-title":"Cancer immunotherapy: an evidence-based overview and implications for practice","volume":"21","author":"Bayer","year":"2017","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.soncn.2024.151583_bib0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.soncn.2024.151583_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1188\/17.CJON.S2.5-7","article-title":"Immunotherapy administration: Oncology Nursing Society recommendations","volume":"21","author":"Wiley","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2024.151583_bib0012","doi-asserted-by":"crossref","unstructured":"Romao R, Mendes AS, Ranchor R, Ramos MJ, Coelho J, Pichel RC, et al. Impact of immune-related adverse events on immune checkpoint inhibitors treated cancer patients' survival: single center experience and literature review. Cancers (Basel). 2023;15(3):888. 10.3390\/cancers15030888","DOI":"10.3390\/cancers15030888"},{"key":"10.1016\/j.soncn.2024.151583_bib0013","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2024.151583_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.iac.2021.12.006","article-title":"Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models","volume":"42","author":"Park","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.soncn.2024.151583_bib0015","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/1078155220901750","article-title":"Staff sensitisation to therapeutic monoclonal antibodies resulting from workplace exposure: a case report","volume":"26","author":"Barrott","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.soncn.2024.151583_bib0016","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/ajco.13943","article-title":"Clinical Oncology Society of Australia position statement: 2022 update to the safe handling of monoclonal antibodies in healthcare settings","volume":"19","author":"Ryan","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2024.151583_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1078155214559113","article-title":"A survey of manufacturing and handling practices for monoclonal antibodies by pharmacy, nursing and medical personnel","volume":"22","author":"Alexander","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.soncn.2024.151583_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.01.005","article-title":"Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers","volume":"128","author":"Paci","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2024.151583_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/IJN.S175340","article-title":"PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells","volume":"14","author":"Xu","year":"2019","journal-title":"Int J Nanomed"},{"issue":"15","key":"10.1016\/j.soncn.2024.151583_bib0020","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers15153886","article-title":"Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.soncn.2024.151583_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104813","article-title":"Considerations for setting occupational exposure limits for novel pharmaceutical modalities","volume":"118","author":"Graham","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.soncn.2024.151583_bib0022","article-title":"Centers for Disease Control and Prevention. National Institute for Occupational Safety and Health (NIOSH)","author":"Connor","year":"2020","journal-title":"Harzardous Drugs: DRAFT NIOSH List of Hazardous Drugs in Healthcare Settings"},{"key":"10.1016\/j.soncn.2024.151583_bib0023","unstructured":"Cancer Insitute NSW. EviQ Education. Monoclonal antibodies and immune checkpoint inhibitors. Accessed 17 September 2022.https:\/\/education.eviq.org.au\/courses\/clinical-and-community-practice\/monoclonal-antibodies-and-immune-checkpoint-inhibi"},{"issue":"Suppl 6a","key":"10.1016\/j.soncn.2024.151583_bib0024","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.12968\/bjon.2015.24.Sup16a.S14","article-title":"Safe handling and administration of MABS: the guidance","volume":"24","author":"McGowan","year":"2015","journal-title":"Br J Nurs"},{"issue":"16 Suppl 1","key":"10.1016\/j.soncn.2024.151583_bib0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.12968\/bjon.2015.24.Sup16a.S3","article-title":"A cautious approach to handling MABs is recommended","volume":"24","author":"Meade","year":"2015","journal-title":"Br J Nur"},{"issue":"8","key":"10.1016\/j.soncn.2024.151583_bib0026","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2146\/sp150001","article-title":"ASHP guidelines on preventing medication errors with chemotherapy and biotherapy","volume":"72","author":"Goldspiel","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.soncn.2024.151583_bib0027","unstructured":"Safe Work Australia. Hazardous chemicals. Accessed 27 October 2022. https:\/\/www.safeworkaustralia.gov.au\/safety-topic\/hazards\/chemicals\/hazardous-chemicals"},{"issue":"1","key":"10.1016\/j.soncn.2024.151583_bib0028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1078155217726160","article-title":"Survey of guidelines and current practices for safe handling of antineoplastic and other hazardous drugs used in 24 countries","volume":"25","author":"Mathias","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.soncn.2024.151583_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front Immunol"},{"issue":"26","key":"10.1016\/j.soncn.2024.151583_bib0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/pai.13339","article-title":"Autoimmune diseases associated with common variable immune deficiency","volume":"31","author":"Lenti","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.soncn.2024.151583_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.soncn.2024.151583_bib0032","first-page":"178","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.soncn.2024.151583_bib0033","series-title":"JBI Manual for Evidence Synthesis","article-title":"Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.soncn.2024.151583_bib0034","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 4: Systematic reviews of text and opinion","author":"McArthur","year":"2020"},{"issue":"18","key":"10.1016\/j.soncn.2024.151583_bib0035","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: Advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.soncn.2024.151583_bib0036","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vhri.2021.06.006","article-title":"Evaluation of the world countries health referral system performance based on World Health Organization indicators using hybrid multi-criteria decision-making model","volume":"28","author":"Bordbar","year":"2022","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.soncn.2024.151583_bib0037","unstructured":"Department of Health and Aged Care. Therapeutic Goods Administration (TGA). What is regulated as a biological. Accessed 22 August 2022. https:\/\/www.tga.gov.au\/resources\/resource\/guidance\/what-regulated-biological#types-define"},{"key":"10.1016\/j.soncn.2024.151583_bib0038","unstructured":"MIMS Australia. MIMS Online. Therapeutic Class. Accessed 07 October 2022. https:\/\/www-mimsonline-com-au.eu1.proxy.openathens.net\/Search\/BrowseTherapeuticClass.aspx?ModuleName=Product%20Info"},{"key":"10.1016\/j.soncn.2024.151583_bib0039","unstructured":"Department of Health and Aged Care. The Pharmaceutical Benefits Scheme. Browse by Body System. Accessed 07 October 2022. https:\/\/www.pbs.gov.au\/browse\/body-system?depth=1&codes=l#l"},{"issue":"10","key":"10.1016\/j.soncn.2024.151583_bib0040","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/imj.12564","article-title":"Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel","volume":"44","author":"Alexander","year":"2014","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.soncn.2024.151583_bib0041","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1188\/21.CJON.343-346","article-title":"Immunotherapy assessment: using a survey instrument to examine oncology nurses\u2019 confidence levels with administration and management","volume":"25","author":"Offner","year":"2021","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.soncn.2024.151583_bib0042","first-page":"b92","volume":"1","author":"Popay","year":"2006","journal-title":"Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. A product from the ESRC Methods Programme"},{"key":"10.1016\/j.soncn.2024.151583_bib0043","series-title":"Essentials of Nursing Research: Appraising Evidence for Nursing Practice","author":"Polit","year":"2022"},{"key":"10.1016\/j.soncn.2024.151583_bib0044","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.12968\/bjon.2015.24.Sup16a.S21","article-title":"Use of closed-system drug transfer devices in the handling and administration of MABs","volume":"24","author":"Meade","year":"2015","journal-title":"Br J Nurs"},{"issue":"5","key":"10.1016\/j.soncn.2024.151583_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197172","article-title":"Guidelines for safe handling of hazardous drugs: a systematic review","volume":"13","author":"Bernabeu-Mart\u00ednez","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.soncn.2024.151583_bib0046","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s11096-018-0711-z","article-title":"Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology","volume":"40","author":"Baldo","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.soncn.2024.151583_bib0047","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11096-011-9595-x","article-title":"Look-alike and sound-alike medicines: risks and \u2018solutions\u2019","volume":"34","author":"Emmerton","year":"2012","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.soncn.2024.151583_bib0048","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.sapharm.2019.08.034","article-title":"Three opportunities for standardization: a literature review of the variation among pharmacists\u2019 patient care services terminology","volume":"16","author":"Gernant","year":"2020","journal-title":"Res Social Adm Pharm"},{"issue":"21-22","key":"10.1016\/j.soncn.2024.151583_bib0049","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1111\/jocn.16835","article-title":"Understanding the workflow of nurses in acute and subacute medical wards: a time and motion study","volume":"32","author":"Kramer","year":"2023","journal-title":"J Clin Nurs"},{"issue":"9","key":"10.1016\/j.soncn.2024.151583_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036264","article-title":"Case for hospital nurse-to-patient ratio legislation in Queensland, Australia, hospitals: an observational study","volume":"10","author":"McHugh","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.soncn.2024.151583_bib0051","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.outlook.2022.01.002","article-title":"Exploring the turbulent nature of nurses\u2019 workflow","volume":"70","author":"Jennings","year":"2022","journal-title":"Nurs Outlook"},{"issue":"8","key":"10.1016\/j.soncn.2024.151583_bib0052","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1097\/PTS.0000000000000528","article-title":"Interruptions to intensive care nurses and clinical errors and procedural failures: a controlled study of causal connection","volume":"17","author":"Santomauro","year":"2021","journal-title":"J Patient Saf"},{"issue":"7","key":"10.1016\/j.soncn.2024.151583_bib0053","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/jonm.12486","article-title":"The impact of interruptions on medication errors in hospitals: an observational study of nurses","volume":"25","author":"Johnson","year":"2017","journal-title":"J Nurs Manag"},{"issue":"3","key":"10.1016\/j.soncn.2024.151583_bib0054","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1097\/PTS.0000000000000335","article-title":"Separate medication preparation rooms reduce interruptions and medication errors in the hospital setting: a prospective observational study","volume":"17","author":"Huckels-Baumgart","year":"2021","journal-title":"J Patient Saf"},{"key":"10.1016\/j.soncn.2024.151583_bib0055","doi-asserted-by":"crossref","DOI":"10.1177\/23333936221094857","article-title":"Exploring nurses\u2019 perceptions of medication error risk factors: findings from a sequential qualitative study","volume":"9","author":"Savva","year":"2022","journal-title":"Global Qualitative Nursing Res"},{"issue":"6","key":"10.1016\/j.soncn.2024.151583_bib0056","first-page":"12","article-title":"How the evolution of immunotherapy will impact oncology nurses","volume":"32","author":"Pirschel","year":"2017","journal-title":"ONS Voice"},{"issue":"8","key":"10.1016\/j.soncn.2024.151583_bib0057","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.7314\/APJCP.2015.16.8.3203","article-title":"Safety management status among nurses handling anticancer drugs: nurse awareness and performance following safety regulations","volume":"16","author":"Jeong","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.soncn.2024.151583_bib0058","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/15459624.2015.1091963","article-title":"Predictors of adherence to safe handling practices for antineoplastic drugs: a survey of hospital nurses","volume":"13","author":"Silver","year":"2016","journal-title":"J Occup Environ Hyg"},{"issue":"6","key":"10.1016\/j.soncn.2024.151583_bib0059","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/1078155219891651","article-title":"Evaluation of awareness and understanding of cancer immunotherapy among healthcare professionals in eastern Saudi Arabia","volume":"26","author":"Hamad","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.soncn.2024.151583_bib0060","first-page":"35","article-title":"Protecting nurses against the risks of occupational exposure to systemic anticancer therapy agents","volume":"20","author":"Simons","year":"2021","journal-title":"Cancer Nurs Pract"},{"issue":"2","key":"10.1016\/j.soncn.2024.151583_bib0061","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3928\/00220124-20160120-03","article-title":"Chemotherapy and biotherapy: What nurses need to know when administering to nononcologic patients","volume":"47","author":"Smith","year":"2016","journal-title":"J Contin Educ Nurs"},{"key":"10.1016\/j.soncn.2024.151583_bib0062","unstructured":"Cancer Insititue NSW sites. EviQ. Essential medicines list. Accessed 07 October 2022. https:\/\/www.eviq.org.au\/essential-medicines-list"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:07:02Z","timestamp":1713877622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208124000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0749208124000044"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151583","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influences Shaping Clinicians\u2019 Monoclonal Antibody and Immune Checkpoint Inhibitor Preparation and Administration Management Practices: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151583"}}